Read our latest updates & insights

On 18 March 2024, Bio-Thera Solutions announced that it is partnering with SteinCares to commercialise two unnamed biosimilars in LATAM.  SteinCares will have exclusive right to distribute and market Bio-Thera’s two biosimilar pharmaceuticals in LATAM and Bio-Thera is respo...

On 17 March 2024, Celltrion USA launched ZYMFENTRA™ (infliximab-dyyb), the first subcutaneous formulation of infliximab approved by the U.S. FDA in 2023.  Zymfentra is approved for maintenance therapy in adults with active ulcerative colitis or Crohn’s disease followi...

On 15 March 2024, the Australian Department of Health and Aged Care published the public summary documents considered at the November 2023 PBAC meeting. Decisions included:

Novo Nordisk’s Wegovy® (semaglutide) – PBAC refused PBS-listing for severe obesity;

On 15 March 2024, CuraTeQ Biologics (a subsidiary of Aurobindo) announced that it successfully completed phase I trials for omalizumab biosimilar (BP11), demonstrating pharmacokinetic and pharmacodynamic equivalence to Genentech’s/Novartis’ US and EU-sourced Xolair®.  The t...

On 14 March 2024, Biocon Biologics announced that it has entered a long-term commercial collaboration with Eris Lifesciences, including to increase access to its biosimilars in India.  The deal, worth INR 12,420 million, involves a 10-year supply agreement with Eris and ove...

On 14 March 2024, AstraZeneca announced that it has entered into an agreement to acquire Amolyt Pharma, a clinical-stage biotechnology company focused on developing novel treatments for rare endocrine diseases.  Amoylt’s portfolio notably includes eneboparatide (AZP-3...